Scott Bruder


“Navigating the Pathway from Research Discoveries to Clinical Practice – Philosophies on Commercial Development”


Scott P. Bruder, MD, PhD, is the Founder and CEO of the Bruder Consulting & Venture Group, and Adjunct Professor of Biomedical Engineering at Case Western Reserve University. He is an insightful and energetic healthcare leader with a 25 year history of bridging basic science, clinical medicine, and industrial development expertise to deliver innovative, commercially successful products that improve patients’ lives around the world. Experience in medical devices, diagnostics, biotechnology, and life science research tools fortify an expansive analytical skill set for this resilient, poised and influential C-Suite executive. An award-winning scientist and clinician, equally comfortable in the laboratory, at the lectern, in the Boardroom or on Capitol Hill, he delivers impactful results by inspiring multi-disciplinary teams to be collaborative, rigorous and decisive. This seasoned Senior Executive, University Professor, and FDA Advisory Committee Member provides a unique bench-to-bedside perspective on unmet needs, development strategy and the path to commercialization. An avid long-distance runner, jazz pianist, devoted husband and dedicated father, his core beliefs are based on the principles of passion, commitment and discipline.


 In order to drive the discovery, development and commercialization of diagnostic and therapeutic products into routine clinical practice with greater speed, certainty and financial efficiency, a symbiotic relationship between academic and industrial investigators is essential.  Approaches that successfully weave the technology, tools and clinical applications from the laboratory bench to the clinical bedside stand a greater chance of being successful in the marketplace.  The purpose of this presentation is to provide practical information and insights regarding the pathways and processes required to bring innovations, particularly in the field of biomaterials and regenerative medicine, to the commercial market.  The presentation will provide an overview of the product development cycle, with special emphasis on recent changes to the regulatory landscape and requirements for reimbursement in the hospital and office setting.  At the close of the discussion, participants will have a greater understanding of the multi-year, multi-step, interactive process required to commercialize new products, along with possible solutions for some of today’s most important health care challenges.